DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.
You may also be interested in...
Rx Drug Ads Should Not Characterize Probability Of Risk As Insignificant, FDA Emphasizes
Agency’s final guidance on presenting quantitative efficacy and risk information in direct-to-consumer advertisements includes an additional example, which specifies risk should not be characterized in a way that suggests it is not important.
Do Drug Ads With Adherence Claims Impact Consumer Perceptions? $722,000 Study Aims To Find Out
Office of Prescription Drug Promotion’s latest study is assessing consumer and physician responses to prescription drug promotions with claims about patient adherence and preference. It is one of 73 research projects OPDP has undertaken.
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.